CSBR Valuation

Champions Oncology Inc

Add to Watchlist

Advanced Chart

7.410

+0.09(1.230%)1D

Overview
Forecast
Valuation
Earnings

CSBR Relative Valuation

CSBR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CSBR is overvalued; if below, it's undervalued.

Historical Valuation

Champions Oncology Inc (CSBR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.72 is considered Undervalued compared with the five-year average of 44.16. The fair price of Champions Oncology Inc (CSBR) is between 8.10 to 13.23 according to relative valuation methord. Compared to the current price of 7.41 USD , Champions Oncology Inc is Undervalued By 8.53%.

Relative Value

Fair Zone

8.10-13.23

Current Price：7.41

8.53%

Undervalued

33.27

Trailing

Forward

32.94

EV/EBITDA

Champions Oncology Inc. (CSBR) has a current EV/EBITDA of 32.94. The 5-year average EV/EBITDA is 21.85. The thresholds are as follows: Strongly Undervalued below -78.19, Undervalued between -78.19 and -28.17, Fairly Valued between 71.87 and -28.17, Overvalued between 71.87 and 121.89, and Strongly Overvalued above 121.89. The current Forward EV/EBITDA of 32.94 falls within the Historic Trend Line -Fairly Valued range.

-407.72

EV/EBIT

Champions Oncology Inc. (CSBR) has a current EV/EBIT of -407.72. The 5-year average EV/EBIT is 26.40. The thresholds are as follows: Strongly Undervalued below -257.34, Undervalued between -257.34 and -115.47, Fairly Valued between 168.27 and -115.47, Overvalued between 168.27 and 310.14, and Strongly Overvalued above 310.14. The current Forward EV/EBIT of -407.72 falls within the Strongly Undervalued range.

1.72

Champions Oncology Inc. (CSBR) has a current PS of 1.72. The 5-year average PS is 1.94. The thresholds are as follows: Strongly Undervalued below 0.45, Undervalued between 0.45 and 1.19, Fairly Valued between 2.68 and 1.19, Overvalued between 2.68 and 3.43, and Strongly Overvalued above 3.43. The current Forward PS of 1.72 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Champions Oncology Inc. (CSBR) has a current P/OCF of 0.00. The 5-year average P/OCF is 2.32. The thresholds are as follows: Strongly Undervalued below -17.53, Undervalued between -17.53 and -7.60, Fairly Valued between 12.25 and -7.60, Overvalued between 12.25 and 22.17, and Strongly Overvalued above 22.17. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-85.77

P/FCF

Champions Oncology Inc. (CSBR) has a current P/FCF of -85.77. The 5-year average P/FCF is 44.11. The thresholds are as follows: Strongly Undervalued below -424.02, Undervalued between -424.02 and -189.96, Fairly Valued between 278.17 and -189.96, Overvalued between 278.17 and 512.23, and Strongly Overvalued above 512.23. The current Forward P/FCF of -85.77 falls within the Historic Trend Line -Fairly Valued range.

Champions Oncology Inc (CSBR) has a current Price-to-Book (P/B) ratio of 26.74. Compared to its 3-year average P/B ratio of 64.52 , the current P/B ratio is approximately -58.56% higher. Relative to its 5-year average P/B ratio of 45.09, the current P/B ratio is about -40.71% higher. Champions Oncology Inc (CSBR) has a Forward Free Cash Flow (FCF) yield of approximately 6.66%. Compared to its 3-year average FCF yield of -1.44%, the current FCF yield is approximately -564.29% lower. Relative to its 5-year average FCF yield of -1.14% , the current FCF yield is about -686.31% lower.

26.74

P/B

Median3y

64.52

Median5y

45.09

6.66

FCF Yield

Median3y

-1.44

Median5y

-1.14

Competitors Valuation Multiple

The average P/S ratio for CSBR's competitors is 4.03, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR) exhibits a P/S ratio of 1.72, which is -57.27% above the industry average. Given its robust revenue growth of -11.76%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CSBR.O

Champions Oncology Inc

Nautilus Biotechnology Inc

Loss

84.40M

QNCX.O

Quince Therapeutics Inc

Loss

86.48M

IPA.O

Immunoprecise Antibodies Ltd

Armata Pharmaceuticals Inc

16.73

88.04M

ANRO.N

Alto Neuroscience Inc

Loss

97.21M

Performance Decomposition

Market capitalization of CSBR increased by 75.59% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -0.78 to -14.85.

The secondary factor is the Revenue Growth, contributed -11.76%to the performance.

Overall, the performance of CSBR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-11.76%

14.00M → 12.36M

Revenue Growth

1803.85%

-0.78 → -14.85

Margin Expansion

-1716.50%

-1.37 → 22.18

P/E Change

75.59%